Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
501 Apheresis Allogeneic Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 62
502 Apheresis Allogeneic Hodgkin’s Disease Hematology 2026 Standard Therapy Italy 34
503 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 20
504 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
505 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 51
506 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 58
507 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Ukraine 45
508 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 41
509 Apheresis Allogeneic Hodgkin's Disease Hematology 2026 Standard Therapy Poland 44
510 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy USA 47
511 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Colombia 57
512 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Australia 72
513 Apheresis Allogeneic EBV-positive nodal T- and NK-cell lymphoma Hematology 2026 Standard Therapy Poland 68
514 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2026 Standard Therapy Russia Federation 48
515 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Finland 69
516 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
517 Apheresis Allogeneic Large Cell Anaplastic Lyphoma ALK Hematology 2026 Standard Therapy Serbia 13
518 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
519 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Lithuania 64
520 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
521 Apheresis Allogeneic Acute Undifferentiated Leukemia Hematology 2026 Standard Therapy USA 16
522 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Czechia 53
523 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
524 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 18
525 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
526 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Lithuania 66
527 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
528 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 41
529 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 72
530 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
531 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 61
532 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 62
533 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 62
534 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Spain 61
535 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
536 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 2
537 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 21
538 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
539 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 71
540 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 61
541 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
542 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 64
543 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
544 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 59
545 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
546 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
547 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 53
548 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy France 26
549 Apheresis Allogeneic Inherited Metabolic Disorder Hematology 2026 Standard Therapy France 50
550 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
551 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 70
552 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Argentina 30
553 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 74
554 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
555 Apheresis Allogeneic Hyper IgE Syndrome Hematology 2026 Standard Therapy Australia 11
556 Apheresis Allogeneic AML FLT3+ Hematology 2026 Standard Therapy Croatia 61
557 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
558 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 58
559 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Iran 3
560 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 59
561 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 58
562 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 10
563 Apheresis Allogeneic Lymphoma – Peripheral T cell Hematology 2026 Standard Therapy United Kingdom 53
564 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 48
565 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 13
566 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Italy 58
567 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 69
568 Apheresis Allogeneic Peripheral T Cell Lymphoma With Haemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy United Kingdom 52
569 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 62
570 Apheresis Allogeneic T-Cell Prolymphocytic Leukemia Hematology 2026 Standard Therapy Italy 72
571 Apheresis Allogeneic Myelodysplastic Disorder Hematology 2026 Standard Therapy Russian Federation 51
572 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 64
573 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
574 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 49
575 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 75
576 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
577 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 58
578 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 52
579 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 69
580 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 20
581 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
582 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Belgium 34
583 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
584 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 69
585 Apheresis Allogeneic T-Cell Acute lymphoblastic leukemia Hematology 2026 Standard Therapy Netherlands 21
586 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 70
587 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 68
588 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 16
589 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
590 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
591 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
592 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 65
593 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 45
594 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
595 Apheresis Allogeneic B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 21
596 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
597 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
598 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 5
599 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Hungary 57
600 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 30
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?